AZD2171
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukaemia
Conditions
Leukaemia, Myelocytic, Acute
Trial Timeline
Apr 1, 2004 → —
NCT ID
NCT00502385About AZD2171
AZD2171 is a phase 1 stage product being developed by AstraZeneca for Leukaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00502385. Target conditions include Leukaemia, Myelocytic, Acute.
What happened to similar drugs?
2 of 8 similar drugs in Leukaemia were approved
Approved (2) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00621725 | Phase 1 | Completed |
| NCT00385203 | Phase 2 | Completed |
| NCT00243347 | Phase 1 | Completed |
| NCT00503412 | Phase 1 | Completed |
| NCT00264004 | Phase 2 | Completed |
| NCT00503477 | Phase 1 | Completed |
| NCT00502385 | Phase 1 | Completed |
| NCT00502164 | Phase 1 | Completed |
| NCT00501605 | Phase 1 | Completed |
Competing Products
20 competing products in Leukaemia